Small molecule glucagon release inhibitors with activity in human islets

PurposeType 1 diabetes (T1D) accounts for an estimated 5% of all diabetes in the United States, afflicting over 1.25 million individuals. Maintaining long-term blood glucose control is the major goal for individuals with T1D. In T1D, insulin-secreting pancreatic islet β-cells are destroyed by the im...

Descripció completa

Dades bibliogràfiques

Autors principals:	Michael A. Kalwat, Karina Rodrigues-dos-Santos, Derk D. Binns, Shuguang Wei, Anwu Zhou, Matthew R. Evans, Bruce A. Posner, Michael G. Roth, Melanie H. Cobb
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2023-04-01
Col·lecció:	Frontiers in Endocrinology
Matèries:	glucagon alpha cell chemical biology high-throughput (HT) screening Type 1 diabetes (T1D)
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1114799/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!